GZPHF (Guangzhou Baiyunshan Pharmaceutical Holdings Co) Revenue: $11,128 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd GZPHF
72 GF Score
Price $2.34
GF Value $3.20
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue?

Guangzhou Baiyunshan Pharmaceutical Holdings Co GZPHF 72 Revenue is $11,128 Mil as of Mar. 2026. GuruFocus rates GZPHF with a GF Score™ of 72/100 and a GF Value™ of $3.20. The stock has 6 warning signs investors should review.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's revenue for the three months ended in Mar. 2026 was $3,377 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $11,128 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue per Share for the three months ended in Mar. 2026 was $2.08. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.85.

During the past 12 months, the average Revenue per Share Growth Rate of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 5.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 15.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Guangzhou Baiyunshan Pharmaceutical Holdings Co's highest 3-Year average Revenue per Share Growth Rate was 43.30% per year. The lowest was -27.90% per year. And the median was 14.40% per year.


Guangzhou Baiyunshan Pharmaceutical Holdings Co  (OTCPK:GZPHF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue Related Terms


Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,835.42 10,153.64 10,576.09 10,300.22 11,025.69

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,100.08 2,696.39 2,775.52 2,278.81 3,377.42

GZPHF vs MCK, COR, CAH: Revenue Comparison

For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue falls into.


GZPHF
72GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd GZPHF
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11,128 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $11,128 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) has a Revenue of $11,128 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Revenue is $11,128 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue of $11,128 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Revenue is $11,128 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) has a current Revenue of $11,128 Mil. The stock's GF Value™ is $3.20, compared to a current price of $2.34 — trading 26.9% below its estimated fair value. The current Revenue is $11,128 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF), the current Revenue is $11,128 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (GZPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of $2.34 is trading 26.9% below its estimated GF Value™ of $3.20.

Key valuation signals for GZPHF:

  • Revenue: $11,128 Mil
  • GF Value™: $3.20 vs. price of $2.34 (26.9% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the GZPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
72GF Score

Get the complete analysis for GZPHF

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$3.20
GF Value